Role of medical intervention in slowing the growth of small abdominal aortic aneurysms

Postgraduate Medical Journal

Volumn 85, Issue 1010, 2009, Pages 688-692

  Cooper, D G ^a   King, J A ^a,b   Earnshaw, J J ^a  

^a GLOUCESTERSHIRE ROYAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXYCYCLINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; ROXITHROMYCIN; ANTIINFECTIVE AGENT;

ABDOMINAL AORTA ANEURYSM; ANEURYSM RUPTURE; DISEASE COURSE; HUMAN; PATHOPHYSIOLOGY; REVIEW; ULTRASOUND; SMOKING CESSATION;

ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIHYPERTENSIVE AGENTS; AORTIC ANEURYSM, ABDOMINAL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; SMOKING CESSATION;

EID: 77949330758     PISSN: 00325473     EISSN: 14690756     Source Type: Journal    
DOI: 10.1136/pgmj.2009.085498     Document Type: Review

References (67)

1. Ashton HA, Buxton MJ, Day NE, et al. The Multicentre Aneurysm Screening Study (MASS) into the effect of abdominal aortic aneurysm screening on mortality in men: a randomised controlled trial. Lancet 2002;360:1531-9. (Pubitemid 35356366)
2. The UK Small Aneurysm Trial Participants. Mortality results for randomised control trial of early elective surgery or ultrasonographic surveillance for small abdominal aortic aneurysms. Lancet 1998;352:1649-55.
3. Hinchliffe RJ, Bruijstens L, MacSweeney STR, et al. A randomised trial of endovascular and open surgery for ruptured abdominal aortic aneurysm: results of a pilot study and lessons learned for future studies. Eur J Vasc Endovasc Surg 2006;32:506-13. (Pubitemid 44490336)
4. Hoornweg LL, Storm-Versloot MN, Ubbink DT, et al. Meta-analysis of mortality of ruptured abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 2008;35:558-70. (Pubitemid 351469939)
5. Vascular Society of Great Britain and Ireland. Fourth National Vascular Database Report. London: Vascular Society of Great Britain and Ireland, 2004:70-1.
6. McCarthy R, Shaw E, Whyman M, et al. Recommendations for screening intervals for small aortic aneurysms. Br J Surg 2003;90:821-6. (Pubitemid 36886383)
7. Powell J, Brady AR. Detection, management and prospects of medical treatment of small abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 2004;24:241-5. (Pubitemid 38197574)
8. Verma S, Lindsay TF. Regression of aortic aneurysms through pharmacologic therapy. N Engl J Med 2006;354:2067-8.
9. Huffman MD, Curci JA, Moore G, et al. Functional importance of connective tissue repair during the development of experimental abdominal aortic aneurysms. Surgery 2000;158:429-38.
10. Forester ND, Cruickshank SM, Scott DJ, et al. Functional characterization of T cells in abdominal aortic aneurysms. Immunology 2005;115:262-70. (Pubitemid 40733413)
11. Ocana E, Bohórquez JC, Pérez-Requena J, et al. Characterisation of T and B lymphocytes infiltrating abdominal aortic aneurysms. Atherosclerosis 2003;170:39-48. (Pubitemid 37083562)
12. Koch AE, Haines GK, Rizzo RJ, et al. Human abdominal aortic aneurysms. Immunophenotypic analysis suggesting an immune-mediated response. Am J Pathol 1990;137:1199-213.
13. Walton LJ, Franklin IJ, Bayston T, et al. Inhibition of prostaglandin E2 synthesis in abdominal aortic aneurysms: implications for smooth muscle cell viability, inflammatory processes, and the expansion of abdominal aortic aneurysms. Circulation 1999;100:48-54. (Pubitemid 29297939)
14. Urbonavicius S, Urbonaviciene G, Honoré B, et al. Potential circulating biomarkers for abdominal aortic aneurysm expansion and rupture - a systematic review. J Vasc Surg 2009;49:455-63.
15. Miller FJ, Sharp WJ, Fang X, et al. Oxidative stress in human abdominal aortic aneurysms: a potential mediator of aneurysmal remodelling. Arterioscler Thromb Vasc Biol 2002;22:560-5. (Pubitemid 34408734)
16. Juvonen J, Juvonen T, Laurila A, et al. Demonstration of Chlamydia pneumoniae in the walls of abdominal aortic aneurysms. J Vasc Surg 1997;25:499-505. (Pubitemid 27136974)
17. Petersen E, Boman J, Persson K, et al. Chlamydia pneumoniae in human abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 1998;15:138-42. (Pubitemid 28142856)
18. Karlsson L, Gnarpe J, Nääs J, et al. Detection of viable Chlamydia pneumoniae in abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 2000;19:630-5. (Pubitemid 30495209)
19. Sodeck G, Domanovits H, Khanakah G, et al. The role of Chlamydia pneumoniae in human aortic disease - a hypothesis revisited. Eur J Vasc Endovasc Surg 2004;28:547-52. (Pubitemid 39307449)
20. Lindholt JS, Ashton HA, Scott RA. Indicators of infection with Chlamydia pneumoniae are associated with expansion of abdominal aortic aneurysms. J Vasc Surg 2001;34:212-5. (Pubitemid 33661115)
21. Vammen S, Lindholt JS, Andersen PL, et al. Antibodies against Chlamydia pneumoniae predict the need for elective surgical intervention on small abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 2001;22:165-8. (Pubitemid 32737462)
22. Thompson RW, Parks WC. Role of matrix metalloproteases in abdominal aortic aneurysm formation. Ann NY Acad Sci 1996;800:157-74. (Pubitemid 27028953)
23. Tilso MD, Elefriades J, Brophy CM. Tensile strength and collagen in abdominal aortic aneurysm disease. In: The cause and management of aneurysms. Greenhalgh RM, Mannick JA, Powell JT, eds. London: WB Saunders, 1990:97-104.
24. Powell JT. Genes predisposing to rapid aneurysm growth. Ann NY Acad Sci 2006;1085:236-41. (Pubitemid 47092013)
25. Wilmink TBM, Quick CRG, Day NE. The association between cigarette smoking and abdominal aortic aneurysms. J Vasc Surg 1999;30:1099-105.
26. MacSweeney ST, Ellis M, Worrell PC, et al. Smoking and growth rate of small abdominal aortic aneurysms. Lancet 1994;344:651-2.
27. Chang JB, Stein TA, Liu JP, et al. Risk factors associated with rapid growth of small abdominal aortic aneurysms. Surgery 1997;121:117-22. (Pubitemid 27091764)
28. Lindholt JS, Heegaard NH, Vammen S, et al. Smoking, but not lipids, lipoprotein(a) and antibodies against oxidised LDL, is correlated to the expansion of abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 2001;21:51-6. (Pubitemid 32186297)
29. Brady AR, Thompson SG, Fowkes FG, et al, UK Small Aneurysm Trial Participants. Abdominal aortic aneurysm expansion: risk factors and time intervals for surveillance. Circulation 2004 6;110:16-21.
30. Brown LC, Powell JT. Risk factors for aneurysm rupture in patients kept under ultrasound surveillance. UK Small Aneurysm Trial Participants. Ann Surg 1999;230:289-96.
31. Bergoing MP, Arif B, Hackmann AE, et al. Cigarette smoking increases aortic dilatation without affecting matrix metalloproteinase-9 and -12 expression in a modified mouse model of aneurysm formation. J Vasc Surg 2007;45:1217-27.
32. Ricci MA, Slaiby JM, Gadowski GR, et al. Effects of hypertension and propranolol upon aneurysm expansion in the Anidjar/Dobrin aneurysm model. Ann N Y Acad Sci 1996 18;800:89-96. (Pubitemid 27028947)
33. Leach SD, Toole AL, Stern H, et al. Effect of beta-adrenergic blockade on the growth rate of abdominal aortic aneurysms. Arch Surg 1988;123:606-9.
34. Gadowski GR, Pilcher DB, Ricci MA. Abdominal aortic aneurysm expansion rate: effect of size and beta-adrenergic blockade. J Vasc Surg 1994;19:727-31. (Pubitemid 24137130)
35. Wilmink AB, Vardulaki KA, Hubbard CS, et al. Are antihypertensive drugs associated with abdominal aortic aneurysms? J Vasc Surg 2002;36:751-7.
36. Biancari F, Mosorin M, Anttila V, et al. Ten-year outcome of patients with very small abdominal aortic aneurysm. Am J Surg 2002;183:53-5. (Pubitemid 34178605)
37. Guessous I, Periard D, Lorenzetti D, et al. The efficacy of pharmacotherapy for decreasing the expansion rate of abdominal aortic aneurysms: a systematic review and meta-analysis. PLoS ONE 2008 26;3:e1895.
38. Lindholt JS, Henneberg EW, Juul S, et al. Impaired results of a randomised double blinded clinical trial of propranolol versus placebo on the expansion rate of small abdominal aortic aneurysms. Int Angiol 1999;18:52-7. (Pubitemid 29253669)
39. Propanolol Aneurysm Trial Investigators. Propranolol for small abdominal aortic aneurysms: results of a randomized trial. J Vasc Surg 2002;35:72-9.
40. Wilmink AB, Day NE, Hubbard CS, et al. Effect of propanolol on the expansion of abdominal aortic aneurysms. A randomised study. Br J Surg 2000;87:499.
41. Michel JB. Renin-angiotensin system and vascular remodelling. Med Sci (Paris) 2004;20:409-13.
42. Nishimoto M, Takai S, Fukumoto H, et al. Increased local angiotensin II formation in aneurysmal aorta. Life Sci 2002;71:2195-205.
43. Pola R, Gaetani E, Santoliquido A, et al. Abdominal aortic aneurysm in normotensive patients: association with angiotensin-converting enzyme gene polymorphism. Eur J Vasc Endovasc Surg 2001;21:445-9. (Pubitemid 32519703)
44. Yeung JM, Heeley M, Gray S, et al. Does the angiotensin-converting enzyme (ACE) gene polymorphism affect rate of abdominal aortic aneurysm expansion? Eur J Vasc Endovasc Surg 2002;24:69-71.
45. Fatini C, Pratesi G, Sofi F, et al. ACE DD genotype: a predisposing factor for abdominal aortic aneurysm. Eur J Vasc Endovasc Surg 2005;29:227-32. (Pubitemid 40267958)
46. Jones GT, Thompson AR, van Bockxmeer FM, et al. Angiotensin II type 1 receptor 1166C polymorphism is associated with abdominal aortic aneurysm in three independent cohorts. Arterioscler Thromb Vasc Biol 2008;28:764-70. (Pubitemid 351651328)
47. Liao S, Miralles M, Kelley BJ, et al. Suppression of experimental abdominal aortic aneurysms in the rat by treatment with angiotensin-converting enzyme inhibitors. J Vasc Surg 2001;33:1057-64. (Pubitemid 33586351)
48. Eagleton MJ, Cho B, Lynch E, et al. Alterations in angiotensin converting enzyme during rodent aortic aneurysm formation. J Surg Res 2006;132:69-73.
49. Hackman DG, Thiruchelvam D, Redelmeier DA. Angiotensin-converting enzyme inhibitors and aortic rupture: a population-based case-control study. Lancet 2006;368:659-65. (Pubitemid 44226485)
50. Gajendragadkar PR, Cooper DG, Walsh SR, et al. Novel uses for statins in surgical patients. Int J Surg 2009;7:285-90.
51. Wilson WR, Evans J, Bell PR, et al. HMG-CoA reductase inhibitors (statins) decrease MMP-3 and MMP-9 concentrations in abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 2005;30:259-62. (Pubitemid 41086295)
52. Steinmetz EF, Buckley C, Shames ML, et al. Treatment with simvastatin suppresses the development of experimental abdominal aortic aneurysms in normal and hypercholesterolemic mice. Ann Surg 2005;241:92-101. (Pubitemid 40040997)
53. Kalyanasundaram A, Elmore JR, Manazer JR, et al. Simvastatin suppresses experimental aortic aneurysm expansion. J Vasc Surg 2006;43:117-24.
54. Schouten O, van Laanen JHH, Boersma E, et al. Statins are associated with a reduced infrarenal abdominal aortic aneurysm growth. Eur J Vasc Endovasc Surg 2006;32:21-6. (Pubitemid 43842752)
55. Mosorin M, Niemela E, Heikkinen J, et al. The use of statins and fate of small aortic aneurysms. Interact Cardiovasc Thorac Surg 2008;7:578-81.
56. Petrinec D, Liao S, Holmes DR, et al. Doxycycline inhibition of aneurysmal degeneration in an elastase-induced rat model of abdominal aortic aneurysm: preservation of aortic elastin associated with suppressed production of 92 ld gelatinase. J Vasc Surg 1996;23:336-46. (Pubitemid 26070722)
57. Longo GM, Xiong W, Greiner TC, et al. Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J Clin Invest 2002;110:625-32. (Pubitemid 34988786)
58. Mosorin M, Juvonen J, Biancari F, et al. Use of doxycycline to decrease the growth rate of abdominal aortic aneurysms: a randomized, double-blind, placebo-controlled pilot study. J Vasc Surg 2001;34:606-10. (Pubitemid 33664907)
59. Baxter BT, Pearce WH, Waltke EA, et al. Prolonged administration of doxycycline in patients with small asymptomatic abdominal aortic aneurysms: report of a prospective (Phase II) multicenter study. J Vasc Surg 2002;36:1-12. (Pubitemid 41122881)
60. Vammen S, Lindholt JS, Ostergaard L, et al. Randomized double-blind controlled trial of roxithromycin for prevention of abdominal aortic aneurysm expansion. Br J Surg 2001;88:1066-72. (Pubitemid 32868660)
61. Holmes DR, Wester W, Thompson RW, et al. Prostaglandin E2 synthesis and cyclooxygenase expression in abdominal aortic aneurysms. J Vasc Surg 1997;25:810-5. (Pubitemid 27227676)
62. Holmes DR, Petrinec D, Wester W, et al. Indomethacin prevents elastase-induced abdominal aortic aneurysms in the rat. J Surg Res 1996;63:305-9. (Pubitemid 26197210)
63. Miralles M, Wester W, Sicard GA, et al. Indomethacin inhibits expansion of experimental aortic aneurysms via inhibition of the cox2 isoform of cyclooxygenase. J Vasc Surg 1999;29:884-92.
64. Franklin IJ, Walton LJ, Brown L, et al. Non-steroidal anti-inflammatory drugs to treat abdominal aortic aneurysm. Br J Surg 1999;86:A707.
65. Gavrila D, Li WG, McCormick ML, et al. Vitamin E inhibits abdominal aortic aneurysm formation in angiotensin II-infused apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2005;25:1671-7. (Pubitemid 41098939)
66. Yoshimura K, Aoki H, Ikeda Y, et al. Regression of abdominal aortic aneurysm by inhibition of c-Jun N-Terminal Kinase in mice. Ann NY Acad Sci 2006;1085:74-81. (Pubitemid 47092002)
67. Baxter BT, Terri MC, Dalman RL. Medical management of small abdominal aortic aneurysms. Circulation 2008;117:1883-9. (Pubitemid 351507477)